Rice paddies and forested hills in Langkawi, Kedah, northern Malaysia

Kratom in Malaysia: Ketum History, Culture, and Current Law

Evidence and law reviewed: July 15, 2026. This educational overview discusses human consumption, reported effects, dependence, and Malaysian law; it is not medical or legal advice.

In Malaysia, kratom is commonly called ketum or biak-biak. The tree Mitragyna speciosa grows naturally in the region, and people in northern Peninsular Malaysia have long consumed water-based leaf preparations for work, social use, pain, and attempts to manage opioid withdrawal. Malaysian studies also document craving, dependence, and physical and psychological withdrawal among regular consumers.

That cultural history exists beside a restrictive federal law. As of July 15, 2026, mitragynine remains listed in Malaysia's Poisons Act schedules. Section 30 controls the import, export, manufacture, mixing, sale, supply, administration, possession, and use of scheduled psychotropic substances. Ordinary consumer possession or use outside the regulations is unlawful, and the current maximum penalty under section 30(5) is a RM100,000 fine, five years' imprisonment, or both.

Ketum is a local name for a real psychoactive plant

Kratom, ketum, and biak-biak refer to the same species when the plant has been identified as Mitragyna speciosa. Kew records the species as native to Malaya as well as other parts of tropical Southeast Asia. Botanical accounts place it in wet lowland habitats, including areas near streams and swamps in Peninsular Malaysia.

The name ketum carries cultural and linguistic context; it is not a chemical specification. Fresh leaf, brewed leaf liquid, dried powder, and concentrated extracts can differ substantially in composition and effect. The botany and habitat guide explains the accepted species identity and why a regional product name alone cannot establish origin.

How ketum has been consumed in northern Malaysia

Malaysian field studies most often describe adults drinking a water-based preparation made from leaves. Participants have reported consuming ketum for stamina, physical endurance, reduced fatigue, pain relief, social or recreational reasons, sexual effects, and relief from opioid withdrawal. These are observed reasons for use and participant reports, not approved medical indications.

People can describe alerting or stimulant-like effects in one pattern of consumption and sedating or opioid-like effects in another. Nausea, dizziness, constipation, sweating, changes in appetite, intoxication, tolerance, craving, dependence, and withdrawal also appear in the broader human record. Pattern, frequency, composition, co-use of other substances, and individual health can change what a person experiences.

A 562-person study recorded daily use and difficulty stopping

A 2012 cross-sectional study used convenience and snowball sampling in a border town between two northern Malaysian states. Researchers conducted face-to-face interviews with 562 respondents. Eighty-eight percent reported daily ketum use, and 90% said their main form was a tea-like extract. Reported reasons included social and recreational use, stamina, physical endurance, pain relief, and sexual performance.

The dependence signal was direct: 460 respondents, or 87%, said they were unable to stop. That figure describes a sample recruited around existing ketum use, not 87% of all Malaysians or all people who ever try kratom. It nevertheless shows why a history limited to “traditional energy” would be incomplete.

The same study illustrates the value of local terminology and setting. It recorded a pattern of frequent consumption in communities where ketum was familiar even though the law was restrictive. The kratom ethnobotany guide explains how community research connects plant form, place, effects, and social meaning.

Ketum and opioid withdrawal in Kedah and Penang

A 2010 study recruited 136 active ketum users in Kedah and Penang. Nearly 77% had a prior drug-use history, and on-site urine screening found that 62 participants were also using other substances. Both shorter- and longer-term ketum users described consuming it to reduce more expensive opioid use and manage withdrawal; shorter-term users were more likely to report heroin use and to identify reduction of other drug dependence as a reason for ketum use.

The study documented self-treatment outside a clinic. It did not randomly assign ketum, verify a treatment response against a control group, or establish ketum as a safe and effective withdrawal medication. Its substantive finding is still important: people in northern Malaysia were deliberately consuming ketum because they believed it reduced opioid withdrawal and helped them use less of more expensive opioids.

That pattern differs from the work-centered account often emphasized in southern Thailand. The border region contains overlapping plant traditions, but the Malaysian sample's drug-use history and reasons for consumption gave ketum a distinct harm-reduction and self-management context.

Dependence and withdrawal were measured in 293 regular users

A 2014 cross-sectional survey recruited 293 regular users from communities across three northern Peninsular Malaysian states. Using structured dependence, withdrawal, and craving instruments, researchers classified more than half of this selected regular-user sample as having severe dependence and 45% as having moderate dependence.

Common physical withdrawal symptoms included muscle spasms and pain, difficulty sleeping, watery eyes or nose, hot flashes, fever, reduced appetite, and diarrhea. Psychological symptoms included restlessness, tension, anger, sadness, and nervousness. More frequent and prolonged consumption was associated with more severe dependence, withdrawal, and difficulty controlling craving.

Those results should remain attached to the population: regular consumers recruited specifically for a dependence study. They do not establish that every consumer develops the same symptoms. They do establish that ketum dependence is not merely a foreign-market concern or an abstract receptor theory; it has been reported and measured in Malaysian communities.

Ketum use also appears inside formal methadone care

A 2022 cross-sectional study recruited 215 adults enrolled in the methadone maintenance program at Hospital Taiping. Of those participants, 106 - 49.3% - reported ketum use. Higher self-reported opioid-withdrawal scores and use of other illicit drugs were associated with greater odds of ketum use, while longer time in the methadone program was associated with lower odds.

This was a single-clinic convenience sample rather than a national estimate. It shows that ketum use can continue alongside formal treatment and polysubstance use. It does not show that ketum caused withdrawal or that it improved methadone outcomes.

Small laboratory studies complicate broad toxicity claims

A 2018 Malaysian study compared 58 regular ketum consumers with 19 healthy controls and analyzed blood counts, liver and kidney measures, glucose, lipids, and other clinical-chemistry markers. Most values did not differ significantly between the groups; HDL and LDL cholesterol were exceptions. Duration and greater reported consumption were not associated with broad changes in the measured blood and chemistry values.

The sample was small, cross-sectional, male, and centered on traditionally brewed ketum liquid from one area. Those data are useful evidence about that group and those tests. They are not proof that long-term consumption has no risks, and they say little about concentrated extracts, adulterated liquids, interactions, or rare adverse events.

For a broader synthesis of direct human evidence, pharmacology, adverse-event records, and remaining uncertainty, see what kratom research knows and is still studying.

The law controls mitragynine, not just a product called “kratom”

Malaysia's legal structure is built around scheduled substances. Mitragynine, the major alkaloid associated with kratom's human effects, appears in the First Schedule Poisons List and the Third Schedule of psychotropic substances. The current First Schedule places mitragynine preparations in Group A unless they fall within the Group D laboratory-use category.

This is why a statement such as “the tree is natural” does not answer the legal question. Leaves and liquids can contain the scheduled alkaloid. Enforcement cases commonly identify mitragynine through chemical analysis of ketum liquid rather than relying only on the common name written on a container.

What section 30(3) prohibits

Section 30(3) of the Poisons Act states that no person may import, export, manufacture, compound, mix, dispense, sell, supply, administer, possess, or use a psychotropic substance except in accordance with regulations made under the Act. Mitragynine's place in the Third Schedule brings it within that control.

The list of verbs matters. Malaysian law is not limited to unlicensed retail sale; it reaches possession and use. The existence of research, pharmacy, and other regulated pathways does not create an ordinary consumer exemption.

What the Group A classification adds

Section 20 sharply limits sale and supply of Group A poisons. It allows wholesale supply by a licensed wholesaler to a licensed pharmacist or another licensed wholesaler, and licensed wholesale supply for immediate export to a purchaser outside Malaysia. Laboratory-use preparations are separately classified in Group D.

These categories concern regulated handling and supply. They are not quality grades and do not mean that a Group A ketum product is available to a retail customer through an ordinary prescription. Current license and research questions belong with Malaysia's Pharmaceutical Services Programme.

A 2025 amendment has not replaced the operative consumer rule

Malaysia's Parliament passed a further Poisons (Amendment) Bill in both houses in 2025. The resulting Act A1774 says it begins only on a date appointed by the Minister through a Gazette notification. As of July 15, 2026, the Ministry of Health's current law page still supplied the Poisons Act consolidated through Act A1666, and no A1774 commencement notification appeared in the federal materials checked for this legal review. The controls described above therefore remain the operative basis for this guide.

Act A1774 is principally an enforcement amendment: its bill text expands definitions, authorized officers, inspection powers, and related procedures. It does not remove mitragynine from the First or Third Schedule. A future commencement would matter for enforcement administration, but it would not turn ordinary ketum possession or use into a lawful consumer activity.

The maximum penalty changed in 2023

The Poisons (Amendment) Act 2022 took effect on January 1, 2023 for the relevant provisions. The current section 30(5) sets a maximum fine of RM100,000, imprisonment for up to five years, or both for violating section 30(3) or the applicable psychotropic-substance regulations.

Older papers and summaries often quote the former maximum of RM10,000 and four years. That number is outdated for conduct governed by the amended provision. The official consolidated Act and current schedules are the appropriate starting point for a present-day legal check.

Malaysia and Thailand now follow different legal paths

Thailand removed kratom from its narcotics list in 2021 and enacted a dedicated Kratom Plant Act in 2022. Malaysia continues to control mitragynine under the Poisons Act. Geography, shared plant traditions, and a land border do not make the two systems interchangeable.

A leaf or bottled liquid obtained on one side of the border can create a serious legal problem on the other. Import, possession, and use each appear in Malaysia's statutory control. Travelers and shippers should verify current official requirements before carrying any leaf, powder, tea, extract, tablet, or other kratom-derived product into Malaysia.

Prohibition has shaped the Malaysian evidence base

Much of the Malaysian human research used cross-sectional interviews, community recruitment, or samples drawn from drug-treatment settings. Researchers could observe real patterns of consumption, effects, dependence, and co-use, but law and stigma affected who was willing to participate and how openly ketum circulated.

That context helps explain why a familiar rural practice can coexist with criminal cases and limited controlled trials. It also cautions against treating one recruited group as a portrait of the entire country. The pre-ecommerce history shows how formal control and community continuity can occupy the same timeline.

“Malay” on a package is not evidence of Malaysian origin or legality

Modern sellers use words such as Green Malay or Malaysian as catalog names. The name does not prove that the leaf was grown in Malaysia, lawfully exported from Malaysia, prepared like ketum in a field study, or chemically similar to the material those participants consumed.

Origin requires traceable records, and a product's present composition requires lot-specific documentation. The traditional knowledge and modern marketing guide explains how regional history becomes detached from current-product evidence. The larger kratom legal architecture also shows why leaf, extract, concentrated compounds, and finished products can be regulated differently.

Read Malaysian ketum research without flattening it

Malaysian studies show people consuming ketum for work, pain, social reasons, and opioid withdrawal. They also show frequent use, difficulty stopping, craving, dependence, and recognizable withdrawal. Small laboratory comparisons did not find broad abnormalities in the measures collected, while treatment-setting studies found ketum use intertwined with opioid withdrawal and other drug use.

No single slogan captures that record. “Traditional” does not mean harmless, “illegal” does not mean no one consumes it, and a participant report of withdrawal relief is not clinical proof of treatment. Keeping the material, population, design, result, and law attached to each statement preserves the reality of ketum in Malaysia.

Sources and further reading

For the earlier documentary trail, Kratom in Colonial-Era Records follows Perak museum material, Leonard Wray's 1907 account, and the limits of official descriptions of ketum consumption.

Written By : Kratom Paradise Editorial Team

Previous Article
Next Article